Results 1 to 10 of about 22,180 (202)

The Effect of Oxcarbazepine on the Pharmacokinetics of Single-Dose Aripiprazole in a Rat Model [PDF]

Medicines
Background/Objectives: A possible pharmacokinetic interaction between a single dose of aripiprazole and multiple-dose pretreatment with oxcarbazepine was investigated in vivo in Wistar albino rats.
Iulia-Maria Ciocotișan, Dana Maria Muntean, Laurian Vlase   +2 more
doaj   +2 more sources

Levels of aripiprazole in the blood with an injection of aripiprazole administered once every two months: a plain language summary of publication [PDF]

Therapeutic Advances in Psychopharmacology
Summary What is this summary about? The information summarized here relates to aripiprazole, a medicine that is used to treat conditions such as schizophrenia and bipolar I disorder.
Yanlin Wang, Matthew Harlin, Frank Larsen, Xiaofeng Wang, Wansu Park, Benjamin Rich, Jogarao V. Gobburu, Arash Raoufinia   +7 more
doaj   +2 more sources

Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports [PDF]

Mental Health Clinician, 2021
Aripiprazole, an atypical antipsychotic, is a metabolic substrate for cytochrome P450 (CYP)3A4 and 2D6. Terbinafine, an antifungal agent used for onychomycosis, is a CYP2D6 inhibitor and could theoretically reduce the metabolism of aripiprazole. However,
Ian R. McGrane, PharmD, Tori J. Lindbloom, PharmD candidate, Robert C. Munjal, MD   +2 more
doaj   +1 more source

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia

BMC Psychiatry, 2023
Background Distinct oral atypical antipsychotics have different effects on autonomic nervous system (ANS) activity. Among them, oral aripiprazole has been linked to dysfunction of the ANS in schizophrenia.
Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Nobuhiko Noguchi, Taku Furuno, Takeshi Asami, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Takashi Saeki, Tadashi Fukushima, Toshio Moritani, Yusuke Saigusa, Akitoyo Hishimoto   +16 more
doaj   +1 more source

A Case of Hypersexuality in a Patient Receiving Aripiprazole for Schizophrenia

Case Reports in Psychiatry, 2021
Aripiprazole is an antipsychotic with partial agonist activity at the dopamine D2 receptor which may lead to compulsive behaviors including hypersexuality.
Lakshmi Priya, Bini Moorthy
doaj   +1 more source

Aripiprazole disrupts cellular synchrony in the suprachiasmatic nucleus and enhances entrainment to environmental light–dark cycles in mice

Frontiers in Neuroscience, 2023
Many patients with psychiatric conditions, such as bipolar disorder and major depressive disorder, frequently experience disruptions in their sleep–wake cycles.
Ruoshi Li, Ruoshi Li, Kosaku Masuda, Kosaku Masuda, Daisuke Ono, Takashi Kanbayashi, Takashi Kanbayashi, Arisa Hirano, Arisa Hirano, Takeshi Sakurai, Takeshi Sakurai   +10 more
doaj   +1 more source

Potentiation of the Antidepressant-Like Effect of Fluoxetine by Aripiprazole in the Mouse Tail Suspension Test

Journal of Pharmacological Sciences, 2008
We examined the effect of the novel atypical antipsychotic drug aripiprazole alone or in combination with the selective serotonin reuptake inhibitor fluoxetine in the mouse tail suspension test.
Junzo Kamei, Shigeo Miyata, Takayuki Sunohara, Atsuko Kamei, Masahiko Shimada, Masahiro Ohsawa   +5 more
doaj   +1 more source

Is aripiprazole similar to quetiapine for treatment of bipolar depression? Results from meta-analysis of Chinese data

Frontiers in Psychiatry, 2022
ObjectiveTo study the similarities and differences in the clinical efficacy of aripiprazole and quetiapine in Chinese patients with bipolar depression through meta-analysis.
Hejian Tao, Jiawei Wang, Dong Shen, Fengli Sun, Fengli Sun, Weidong Jin, Weidong Jin   +6 more
doaj   +1 more source

Relationship between subjective well-being and aripiprazole: an [11C]raclopride PET study

Scientific Reports, 2022
The dopamine blockade by antipsychotics trigger subjective dysphoria. Compared with D2 antagonists, aripiprazole, a D2 partial agonist, was expected to produce a different experience.
Seoyoung Kim, Elena Younhye Ock, Jun Soo Kwon, Euitae Kim   +3 more
doaj   +1 more source

Aripiprazole-induced transient myopia: A rare entity

Indian Journal of Ophthalmology, 2018
Aripiprazole is a new drug for the treatment of adults with schizophrenia. Ocular side effects of aripiprazole are very rare. Review of literature revealed few cases of aripiprazole-induced myopia.
K V Praveen Kumar, P Chiranjeevi, Md Shahid Alam   +2 more
doaj   +1 more source